Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Methylphenidate Transdermal System in Pediatric ADHD
NCT00151957Phase 3Completed
- Sponsor
- Noven Therapeutics, LLC
- Start
- Oct 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Noven Therapeutics, LLC. Primary endpoint: Treatment emergent adverse events at 12 months. Started Oct 2004; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00151957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151957.